Stay updated with breaking news from Mark Mallon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Segall Bryant & Hamill LLC decreased its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO – Get Rating) by 50.4% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 39,654 shares of the medical research company’s stock after selling 40,345 shares during the quarter. Segall Bryant […]
Recent Highlights:Full year 2021 consolidated revenue increased 9% year-over-year; excluding COVID-19 PCR testing revenue, consolidated revenue increased 16%Fourth quarter consolidated revenue was flat
FT. MYERS, FL / ACCESSWIRE / February 14, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, has announced
In addition, Inivata has submitted to the MolDX program in the US for the reimbursement of RaDaR for clinical testing.
NeoGenomics Announces RaDaR(TM) Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program - read this article along with other careers information, tips and advice on BioSpace